医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q2FY16 Results on Oct 29, 2015 // Earnings Call Slated for Oct 29, 6.30 PM IST / 9.00 AM EDT

2015年10月19日 PM07:39
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half year ended September 30, 2015 on Thursday, October 29, 2015 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.

       

Summary of Events

           

Event

   

Date and Time

   

Medium

Release of financial results     October 29th, after the Board Meeting    

Email, Media, Company website, Business Wire

Earnings Call     October 29th, 6.30 PM IST / 9:00 AM EDT     Hosted by the Company (Details below)
Webcast of Earnings Call    

October 29th, 6.30 PM IST / 9.00 AM EDT through Nov 2nd

   

URL available on Company’s website, www.drreddys.com

Transcript of the Earnings call     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

 

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through November 2, 2015. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website

 

Conference Dial-In Numbers

Primary Number:

 

+91 22 3960 0616

Secondary Number:  

+91 22 6746 5826

The numbers listed above are universally accessible from all networks and all countries.

Local Access Number:

6000 1221
Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada
Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune
Accessible from all carriers.

 

International Toll Free Number:

USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448

 
 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to accelerating access to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151019005636/en/

CONTACT

DR. REDDY’S LABORATORIES LTD.
INVESTOR RELATIONS
KEDAR
UPADHYE, +91-40-66834297
kedaru@drreddys.com
or
MEDIA
RELATIONS

CALVIN PRINTER, +91-40-49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作
  • ベルタンとザイモリサーチが新しい連携を発表
  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin